Clinical Trial Detail

NCT ID NCT02048943
Title Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements no
Sponsors Roswell Park Cancer Institute
Indications

Advanced Solid Tumor

pancreatic cancer

Therapies

Dovitinib + Gemcitabine + Nab-paclitaxel

Nab-paclitaxel

Dovitinib

Age Groups: adult senior

No variant requirements are available.